Trials / Unknown
UnknownNCT02771301
Safety and Efficacy of IDH1R132H-DC Vaccine in Gliomas
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Hebei Yanda Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This trial is aimed at evaluating the safety and efficacy of IDH1R132H-DC vaccine in glioma with IDH1R132H mutation.
Detailed description
Eligible patients that provide written informed consent will undergo apheresis to collect blood mononuclear cells for vaccine production. All patients will receive mature dendritic cells for a total of 12 vaccine doses.The DC vaccine will be given subcutaneously every four weeks. Peripheral blood will be taken two weeks after injection each time to monitor the immune response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | dendritic cells | Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2019-01-01
- Completion
- 2019-01-01
- First posted
- 2016-05-13
- Last updated
- 2016-05-13
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02771301. Inclusion in this directory is not an endorsement.